Skip to main content

Advertisement

Table 5 Univariate and multivariate anlaysis for PFS and OS

From: Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

  PFS Univariate Pvalue Multivariate Pvalue HR 95% CI OS Univariate Pvalue Multivariate Pvalue HR 95% CI
CAIX-levels
Elevated vs. non elevated
< 0.01 0.06 1.38 0.99 - 1.92 < 0.01 .04 1.68 1.02 - 2.77
TIMP levels
Elevated vs. non elevated
< 0.01 0.21 1.26 0.88 - 1.80 < 0.01 .09 1.55 0.93 - 2.58
Therapy line
> 1st line vs. 1st line
< 0.01 < 0.01 2.61 1.84 - 3.70 < 0.01 < 0.01 2.61 1.45 - 4.70
Grading
3 vs. 1/2
0.49 - - - 0.41 - - -
Menopusal status
Premeno vs. postmeno
0.06 - - - 0.49 - - -
ER status
Negative vs. positive
0.03 0.01 1.51 1.90 - 2.10 0.21 - - -
PR status
Negative vs. positive
0.07 - - - 0.57 - - -
HER2 status
Negative vs. positive
0.17 - - - 0.40 - - -
Number of metastatic sites
Multiple vs. single
< 0.01 0.02 1.52 1.08 - 2.15 < 0.01 0.27 1.37 0.78 - 2.40
CTC count
≥ 5 cells vs. < 5 cells
0.12 - - - < 0.01 < 0.01 2.48 1.46-4.36
  1. CAIX, carbonic anhydrase IX; CI, confidence interval; CTC, circulating tumor cell; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor; TIMP, tissue inhibitor of metalloproteinase.